ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
3 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
703
|
284K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
3 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
703
|
284K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
3 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
703
|
284K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
5 |
02/04/22 |
02/04/22 |
ASX - By Stock
|
703
|
284K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
10 |
01/04/22 |
01/04/22 |
ASX - By Stock
|
703
|
284K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
5 |
01/04/22 |
01/04/22 |
ASX - By Stock
|
703
|
284K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
CHM Fundamental's
|
|
Specyray
|
31 |
8.6K |
3 |
25/03/22 |
25/03/22 |
ASX - By Stock
|
31
|
8.6K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
CHM Fundamental's
|
|
Specyray
|
31 |
8.6K |
4 |
25/03/22 |
25/03/22 |
ASX - By Stock
|
31
|
8.6K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
CHM Fundamental's
|
|
Specyray
|
31 |
8.6K |
4 |
25/03/22 |
25/03/22 |
ASX - By Stock
|
31
|
8.6K
|
4
|
|
ASX - By Stock
|
4DS |
Re:
4DS acquisition imminent
|
|
Specyray
|
248 |
64K |
2 |
24/03/22 |
24/03/22 |
ASX - By Stock
|
248
|
64K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER
|
|
Specyray
|
19 |
8.7K |
12 |
23/03/22 |
23/03/22 |
ASX - By Stock
|
19
|
8.7K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
CHM Fundamental's
|
|
Specyray
|
31 |
8.6K |
12 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
31
|
8.6K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
CHM Fundamental's
|
|
Specyray
|
31 |
8.6K |
18 |
19/03/22 |
19/03/22 |
ASX - By Stock
|
31
|
8.6K
|
18
|
|
ASX - By Stock
|
CHM |
CHM Fundamental's
|
|
Specyray
|
31 |
8.6K |
13 |
19/03/22 |
19/03/22 |
ASX - By Stock
|
31
|
8.6K
|
13
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Extension of Closing Date for Retail Entitlement Offer
|
|
Specyray
|
36 |
13K |
14 |
12/03/22 |
12/03/22 |
ASX - By Stock
|
36
|
13K
|
14
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Specyray
|
24K |
12M |
44 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
24K
|
12M
|
44
|
|
ASX - By Stock
|
4DS |
Re:
Ann: Testing Capability Upgrade & Management Changes
|
|
Specyray
|
708 |
190K |
5 |
03/03/22 |
03/03/22 |
ASX - By Stock
|
708
|
190K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
21 |
02/03/22 |
02/03/22 |
ASX - By Stock
|
703
|
284K
|
21
|
|
ASX - By Stock
|
4DS |
Re:
Ann: Testing Capability Upgrade & Management Changes
|
|
Specyray
|
708 |
190K |
8 |
02/03/22 |
02/03/22 |
ASX - By Stock
|
708
|
190K
|
8
|
|
ASX - By Stock
|
4DS |
Re:
Ann: Testing Capability Upgrade & Management Changes
|
|
Specyray
|
708 |
190K |
17 |
14/02/22 |
14/02/22 |
ASX - By Stock
|
708
|
190K
|
17
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
Specyray
|
450 |
157K |
13 |
10/02/22 |
10/02/22 |
ASX - By Stock
|
450
|
157K
|
13
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
5 |
08/02/22 |
08/02/22 |
ASX - By Stock
|
703
|
284K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Encouraging data from 2nd dose cohort in CLTX CAR T trial
|
|
Specyray
|
27 |
7.9K |
17 |
08/02/22 |
08/02/22 |
ASX - By Stock
|
27
|
7.9K
|
17
|
|
ASX - By Stock
|
RAD |
RAD media
|
|
Specyray
|
7 |
3.3K |
6 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
7
|
3.3K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Specyray
|
14K |
6.7M |
10 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
14K
|
6.7M
|
10
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
2 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
703
|
284K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
8 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
703
|
284K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Sponsored Research Agreement with University of Pennsylvania
|
|
Specyray
|
6 |
2.3K |
7 |
01/02/22 |
01/02/22 |
ASX - By Stock
|
6
|
2.3K
|
7
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Specyray
|
30 |
8.9K |
0 |
27/01/22 |
27/01/22 |
ASX - By Stock
|
30
|
8.9K
|
0
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Specyray
|
30 |
8.9K |
3 |
27/01/22 |
27/01/22 |
ASX - By Stock
|
30
|
8.9K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric receives US patent covering CLTX CAR technology
|
|
Specyray
|
21 |
8.2K |
7 |
27/01/22 |
27/01/22 |
ASX - By Stock
|
21
|
8.2K
|
7
|
|
ASX - By Stock
|
RAD |
Re:
Ann: RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
|
|
Specyray
|
5 |
2.5K |
5 |
24/01/22 |
24/01/22 |
ASX - By Stock
|
5
|
2.5K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
CLTX-CAR T is a game changer
|
|
Specyray
|
83 |
39K |
8 |
19/01/22 |
19/01/22 |
ASX - By Stock
|
83
|
39K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
CLTX-CAR T is a game changer
|
|
Specyray
|
83 |
39K |
13 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
83
|
39K
|
13
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Specyray
|
24K |
12M |
33 |
14/01/22 |
14/01/22 |
ASX - By Stock
|
24K
|
12M
|
33
|
|
ASX - By Stock
|
PAR |
Re:
The Good Oil
|
|
Specyray
|
9 |
5.8K |
18 |
09/01/22 |
09/01/22 |
ASX - By Stock
|
9
|
5.8K
|
18
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
Specyray
|
380 |
177K |
10 |
06/01/22 |
06/01/22 |
ASX - By Stock
|
380
|
177K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
Specyray
|
380 |
177K |
14 |
04/01/22 |
04/01/22 |
ASX - By Stock
|
380
|
177K
|
14
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Specyray
|
24K |
12M |
1 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
24K
|
12M
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Specyray
|
24K |
12M |
6 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
24K
|
12M
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Specyray
|
24K |
12M |
8 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
24K
|
12M
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Successful completion of 2nd dose cohort in CLTX CAR T trial
|
|
Specyray
|
12 |
5.5K |
10 |
19/12/21 |
19/12/21 |
ASX - By Stock
|
12
|
5.5K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Specyray
|
703 |
284K |
4 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
703
|
284K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Successful completion of 2nd dose cohort in CLTX CAR T trial
|
|
Specyray
|
12 |
5.5K |
16 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
12
|
5.5K
|
16
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Successful completion of 2nd dose cohort in CLTX CAR T trial
|
|
Specyray
|
12 |
5.5K |
10 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
12
|
5.5K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
CORE-NK Platform
|
|
Specyray
|
23 |
8.8K |
12 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
23
|
8.8K
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Specyray
|
14K |
6.7M |
50 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
14K
|
6.7M
|
50
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Specyray
|
14K |
6.7M |
26 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
14K
|
6.7M
|
26
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
Specyray
|
380 |
177K |
5 |
14/12/21 |
14/12/21 |
ASX - By Stock
|
380
|
177K
|
5
|
|
ASX - By Stock
|
4DS |
Re:
4DS - Anything but Charting
|
|
Specyray
|
30K |
13M |
33 |
13/12/21 |
13/12/21 |
ASX - By Stock
|
30K
|
13M
|
33
|
|